24 April 2025 : Review article
Global Guidelines and Trends in HPV Vaccination for Cervical Cancer Prevention
Wojciech Miazga
1ABCDEF, Tomasz Tatara 2ADF, Mariusz Gujski 3DEF, Jarosław Pinkas 1EF, Janusz Ostrowski 1EF, Urszula Religioni 1CDEF*
DOI: 10.12659/MSM.947173
Med Sci Monit 2025; 31:e947173
Table 1 List of recommendations included in this study.
| Organization/ year | Optimal/priority age of vaccination target population | Sex of the target population for vaccination (F, female; M, male) | Upper age of target population for catch-up vaccination | Recommended vaccination | Administration scheme |
|---|---|---|---|---|---|
| Australian Government Department of Health, 2023 []6 | 12–13 years | F and M | 25 years | 9vHPV | 1 dose |
| Joint Committee on Vaccination and Immunization, 2023 []7 | 12–13 years | F and M | 25 years | 9vHPV | 2 doses |
| Polish Society for Colposcopy and Cervical Pathophysiology, 2023 []8 | 12–13 years | F | 26 years | 9vHPV | 1 or 2 doses |
| Royal College of Physicians of Ireland/National Immunization Advisory Committee, 2023 []9 | 12–13 years | F and M | 25 years | 9vHPV | 1 dose |
| Health Council of the Netherland, 2022 []10 | 9 years | F and M | 26 years | – | 2 doses |
| Polish Scientific Societies, 2022 []11 | 11–13 years | F | – | Based on an independent pharmacoeconomic analysis | – |
| World Health Organization, 2022 []12 | 9–14 years | F | 20 years | Based on significant local epidemiological data on HPV infections | 1 or 2 doses |
| American Academy of Family Physicians, 2021 []13 | 11–12 years | F and M | 26 years | – | 2 doses |
| Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, 2021 []14 | 9–14 years | F and M | 26 years | – | 2 doses |
| Center for Disease Prevention and Control, 2021 []15 | 11–12 years | F and M | 26 years | – | 2 doses |
| National Cancer Institute, 2021[]16 | 11–12 years | F and M | 26 years | – | 2 doses |
| American College of Obstetricians and Gynecologists, 2020 []17 | 11–12 years | F and M | 26 years | – | – |
| American Cancer Society, 2020 []18 | 9–12 years | F and M | 26 years | – | – |
| Haute Autorité de Santé, 2020 []19 | 11–14 years | F and M | 19 years | 9vHPV | – |
| Advisory Committee on Immunization Practices, 2019 []20 | 11–12 years | F and M | 26 years | – | – |
| European Society of Gynecologic Oncology/European Federation for Colposcopy, 2019 []21 | 9–13 years | F and M | 25 years | – | 2 doses |